BioSpace News Archive

So-Young International Inc. announced that it will report its financial results for the third quarter ended September 30, 2019, before U.S. markets open on December 5, 2019.

Amphastar Pharmaceuticals, Inc. announced that Jason Shandell, President will be presenting at the Jefferies London Healthcare Conference on Thursday, November 21, 2019 at 3:20 p.m. GMT in Aldwych, London, UK.

Update on Phase 1 Dose-Escalation portion of ongoing Phase 1/2 clinical trial, with specific focus on dosing schema, patient enrollment, and safety data, to be presented at SMR on November 20, 2019

Envista Holdings Corporation (NYSE: NVST) announced it intends to file a Form S-4/S-1 Registration Statement today with the Securities and Exchange Commission (SEC) in connection with Danaher’s (NYSE: DHR) proposed offer to exchange shares of Envista common stock it owns for shares of Danaher common stock

Promedior, Inc., today announced that it has entered into a definitive merger agreement for Roche (SIX: RO, ROG; OTCQX: RHHBY) to acquire Promedior

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency, has adopted a positive opinion for Rigel’s Marketing Authorization Application (MAA) for fostamatinib disodium hexahydrate (fostamatinib) for the treatment of chronic immune thrombocytopenia in adult patients who are refractory to other treatments.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that Bruce Given, M.D., Arrowhead’s chief operating officer and head of R&D, plans to retire on May 1, 2020, after a more than 30 year career in biotechnology and pharmaceutical research, development, and sales and marketing

BIONIK Laboratories Corp. (OTCQB: BNKL) (“BIONIK” or the “Company”), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced financial results for the second quarter of fiscal year 2020, ended September 30, 2019.

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that Chief Executive Officer Jonathan P. Mow will present a company overview at the Stifel 2019 Healthcare Conference

OPKO Health, Inc. (OPK) today announced that Novitas Solutions, Inc. has issued its final Local Coverage Determination (LCD) for Medicare payments for the 4Kscore® test with defined coverage criteria, effective December 30, 2019.